Table 2.

Comparison of TMB, D50, and immune factors pre-NAC and post-NAC in general population or patients with different curative effects.

	Non-pCR	pCR	p	Non-MPR	MPR	p	Non-ORR	ORR	p	ALL
TMB Pre-NAC	10.639	2.310	0.043	12.347	3.409	0.007	21.538	5.964	0.001	9.503
TMB Post-NAC	6.882	2.821	0.699	8.513	1.65	0.023	18.923	2.624	0.000	6.329
p	0.010	0.879		0.041	0.176		0.500	0.017		0.014
D50 Pre-NAC	2.066	0.467	0.010	2.203	1.086	0.018	2.560	1.638	0.034	1.848
D50 Post-NAC	2.037	2.833	0.125	1.667	3.171	0.031	1.940	2.206	0.875	2.146
p	0.658	0.028		0.125	0.028		0.343	0.332		0.638
CD3 Pre-NAC	0.059	0.143	0.050	0.059	0.094	0.041	0.039	0.079	0.077	0.070
CD3 Post-NAC	0.153	0.050	0.191	0.132	0.153	0.490	0.151	0.135	0.906	0.139
p	0.003	0.109		0.019	0.499		0.068	0.177		0.050
CD8 Pre-NAC	0.008	0.025	0.025	0.009	0.012	0.573	0.004	0.012	0.034	0.011
CD8 Post-NAC	0.019	0.008	0.356	0.0154	0.023	0.535	0.005	0.022	0.021	0.017
p	0.000	0.109		0.001	0.735		0.144	0.055		0.021
CD4 Pre-NAC	0.040	0.059	0.166	0.055	0.024	0.410	0.030	0.046	0.693	0.021
CD4 Post-NAC	0.039	0.008	0.343	0.031	0.045	0.462	0.038	0.036	0.346	0.036
p	0.959	0.028		0.128	0.465		0.655	0.515		0.657
PD1 Pre-NAC	0.024	0.004	0.693	0.030	0.005	0.143	0.004	0.024	0.693	0.021
PD1 Post-NAC	0.012	0.008	0.752	0.013	0.009	0.705	0.021	0.009	0.480	0.011
p	0.575	0.039		0.499	0.715		0.180	0.314		0.722
TIM3 Pre-NAC	0.008	0.001	0.324	0.010	0.002	0.107	0.001	0.008	0.324	0.007
TIM3 Post-NAC	0.003	0.0004	0.343	0.002	0.006	0.186	0.002	0.003	0.814	0.003
p	0.241	0.635		0.043	0.465		0.655	0.214		0.213
PD1CD8 Pre-NAC	0.001	0.0007	0.072	0.001	0.0003	0.858	0.00007	0.001	0.229	0.001
PD1CD8 Post-NAC	0.001	0.0009	1.000	0.0014	0.0010	0.237	0.00023	0.002	0.108	0.002
p	0.025	0.593		0.140	0.128		0.068	0.068		0.027
PD1CD4 Pre-NAC	0.004	0.001	0.423	0.006	0.000	0.158	0.001	0.004	1.000	0.004
PD1CD4 Post-NAC	0.003	0.000	0.114	0.003	0.001	0.705	0.008	0.001	0.099	0.002
p	0.799	0.036		0.398	0.465		0.180	0.173		0.657
TIM3CD8 Pre-NAC	0.0006	0.000	0.335	0.001	0.000	0.074	0.000	0.001	0.335	0.0005
TIM3CD8 Post-NAC	0.0002	0.000	0.202	0.000	0.000	0.849	0.000	0.000	0.634	0.0002
p	0.953	0.108		0.345	0.109		0.180	0.735		0.477
TIM3 CD4 Pre-NAC	0.004	0.0003	1.000	0.005	0.000	0.045	0.000	0.004	0.689	0.003
TIM3 CD4 Post-NAC	0.001	0.000	0.114	0.001	0.002	0.571	0.001	0.001	0.480	0.001
p	0.575	0.083		0.091	0.273		0.180	0.314		0.953
CD4/CD8 Pre-NAC	5.256	5.145	0.197	6.392	2.929	0.734	3.025	5.680	0.519	5.237
CD4/CD8 Post-NAC	1.682	1.806	0.343	1.778	1.545	0.571	3.744	1.238	0.034	1.693
p	0.086	0.092		0.063	0.593		0.180	0.025		0.047

NAC, neo-adjuvant chemotherapy; Clinical response was evaluated according to RECIST (the Response Evaluation Criteria in Solid Tumors) 1.1; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; MPR, 10% or less percentage of residual viable tumor cells after neoadjuvant therapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer. The bold values were those p values less than 0.05.